Lyra therapeutics to present study results for lyr-210 and lyr-220 in two presentations at the ars and aao-hns annual meetings

Watertown, mass., sept. 27, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra), (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (crs), today announced that the company will present results from the phase 3 enlighten 1 study for lyr-210, the company's lead product candidate for crs, at the 70th annual meeting of the american rhinologic society (ars), taking place september 27-28 in miami. the company will also present additional results from the phase 2 beacon study for lyr-220 in adult patients with crs who have had prior ethmoid sinus surgery at the annual meeting of the american academy of otolaryngology–head and neck surgery (aao-hns), taking place september 28 - october 1 in miami.
LYRA Ratings Summary
LYRA Quant Ranking